Drugs / PRLX 93936
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00528047 | Aug 2007 → Mar 2011 | cancer | Prolexys Pharmaceuticals | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01695590 | Mar 2012 → Mar 2014 | plasma cell myeloma | Prolexys Pharmaceuticals | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PRLX 93936 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01695590 ↗ |
| Route | Intravenous | “administered intravenously” NCT00528047 ↗ |